Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years

Next Previous
Search
Trial Profile

Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Bortezomib; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms GEM2017FIT

    • Most Recent Events

    • 10 Dec 2024 Results (n=230) investigating the clinical value of PRD assessed by mass-spec (MS) and MRD by Next Generation Flow in non-transplant eligible pts presented at the 66th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Primary endpoint has been met, (the MRD(-) rate (NGF 10-5) at the end of induction to compare both experimental arms, KRd and D-KRd to the control-one, VMP-Rd), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top